ReviewJournal of cancer research and clinical oncology2025
The impact of miRNAs on epithelial-mesenchymal transition in lung cancer and the latest advances in their use as diagnostic markers.
Review in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Diagnostic and prognostic value of lncSPATA8-AS1 in prostate cancer and its regulatory effect on tumor progression.Cancer biology & therapy · 2026Article
- Fluorescence/surface-enhanced Raman scattering dual-mode sensor based on Ag/CQDs/ZIF-8 for human carboxylesterase 1 detection.Mikrochimica acta · 2026Article
- The Role of Low CD36 Expression in the Development of Non-Small Cell Lung Cancer and Its Potential for Therapy.Cancers · 2026Review
- MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeLung cancer is currently the most common malignant tumor worldwide and one of the leading causes of cancer-related deaths, posing a serious threat to human health. MicroRNAs (miRNAs) are a class of endogenous non-coding small RNA molecules that regulate gene expression and are involved in various biological processes associated with lung cancer. Understanding the mechanisms of lung carcinogenesis and detecting disease biomarkers may enable early diagnosis of lung cancer.
methodsEpithelial-mesenchymal transition (EMT) is a critical biological process through which tumor cells acquire migratory and invasive capabilities, playing an important role in the progression of lung cancer. miRNAs regulate the EMT process in lung cancer cells by targeting transcription factors such as Snail, Slug, and ZEB1/2, as well as modulating signaling pathways including TGF-β and Wnt/β-catenin, thereby enhancing their migratory and invasive abilities.
resultsNSCLC has been comprehensively elucidated in terms of its pathogenesis, and the detection and therapeutic approaches targeting miRNAs for NSCLC have been systematically summarized.
conclusionThis review examines the impact of miRNAs on tumor invasiveness through the regulation of key factors or signaling pathways, as well as their potential as biomarkers for the early diagnosis of lung cancer. It provides a theoretical foundation for studying the mechanisms of lung cancer metastasis and developing more precise detection and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.